These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

183 related items for PubMed ID: 2705754

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. In vitro sensitivity of various human tumors to 1-beta-D-arabinofuranosylcytosine and N4-behenoyl-1-beta-D-arabinofuranosylcytosine.
    Maehara Y, Kusumoto T, Kusumoto H, Anai H, Sugimachi K.
    Chemotherapy; 1989; 35(3):181-6. PubMed ID: 2766858
    [Abstract] [Full Text] [Related]

  • 7. Membrane affinity and metabolism of N4-palmitoyl-1-beta-D-arabinofuranosylcytosine into cultured KB cells.
    Tsuruo T, Iida H, Hori K, Tsukagoshi S, Sakurai Y.
    Cancer Res; 1981 Nov; 41(11 Pt 1):4484-8. PubMed ID: 7306971
    [Abstract] [Full Text] [Related]

  • 8. [The simultaneous determination of Ara-U and Ara-C, urinary metabolites of N4-behenoyl-1-beta-D-arabinofuranosylcytosine by mass fragmentography (author's transl)].
    Makino Y, Matsubara Y, Watanabe K, Hirobe M.
    Yakugaku Zasshi; 1982 Jan; 102(1):49-55. PubMed ID: 7086638
    [No Abstract] [Full Text] [Related]

  • 9. [Clinical and pharmacokinetic studies of high dose N4-behenoyl-1-beta-D-arabinofuranosylcytosine].
    Yoshida T, Nakamura S, Ohtake S, Ito K, Kobayashi K, Kanno M, Hirai J, Tachimori K, Matsuda T.
    Gan To Kagaku Ryoho; 1987 Jun; 14(6 Pt 1):1820-4. PubMed ID: 3592717
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Metabolism of the new liposomal anticancer drug N4-octadecyl-1-beta-D-arabinofuranosylcytosine in mice.
    Koller-Lucae SK, Suter MJ, Rentsch KM, Schott H, Schwendener RA.
    Drug Metab Dispos; 1999 Mar; 27(3):342-50. PubMed ID: 10064564
    [Abstract] [Full Text] [Related]

  • 17. Enhancement of the toxicity and DNA incorporation of arabinosyl-5-azacytosine and 1-beta-D-arabinofuranosylcytosine by cyclopentenyl cytosine.
    Grem JL, Allegra CJ.
    Cancer Res; 1990 Nov 15; 50(22):7279-84. PubMed ID: 1699659
    [Abstract] [Full Text] [Related]

  • 18. [Antitumor effects of Behenoyl-ara-C (BH-AC) in combination with Idarubicin (IDA) in P 388 leukemic cell bearing mice].
    Watanabe A, Kuriyama H, Kiyota T.
    Gan To Kagaku Ryoho; 1996 Feb 15; 23(3):291-6. PubMed ID: 8712821
    [Abstract] [Full Text] [Related]

  • 19. A radioimmunoassay method for 1-beta-D-arabinofuranosyluracil using antibodies directed against 1-beta-D-arabinofuranosylcytosine.
    Okabayashi T, Mihara S, Moffatt JG.
    Cancer Res; 1977 Feb 15; 37(2):625-8. PubMed ID: 12864
    [Abstract] [Full Text] [Related]

  • 20. Potentiation of 1-beta-D-arabinofuranosylcytosine metabolism and cytotoxicity by 2,3-dihydro-1H-imidazolo[1,2-b]pyrazole in the human promyelocytic leukemic cell, HL-60.
    Grant S, Bhalla K, Rauscher F, Cadman E.
    Cancer Res; 1983 Nov 15; 43(11):5093-100. PubMed ID: 6577943
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.